Agonists of GLP-1 and GIP receptors have rightfully attracted significant scientific and clinical attention and have already secured their place in the treatment of severe cardiometabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity [1]. This evidence concerns the gene GCG and Obesity.